Works matching IS 03407004 AND DT 2018 AND VI 67 AND IP 8

Results: 15

Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1317, doi. 10.1007/s00262-018-2191-3

By:

Calabrò, Luana;
Morra, Aldo;
Cornelissen, Robin;
Aerts, Joachim;
Maio, Michele

Publication type:

Article

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1305, doi. 10.1007/s00262-018-2190-4

By:

Brown, Zachary J.;
Yu, Su Jong;
Heinrich, Bernd;
Ma, Chi;
Fu, Qiong;
Sandhu, Milan;
Agdashian, David;
Zhang, Qianfei;
Korangy, Firouzeh;
Greten, Tim F.

Publication type:

Article

Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1297, doi. 10.1007/s00262-018-2189-x

By:

Karpathiou, Georgia;
Chauleur, Celine;
Hathroubi, Sirine;
Habougit, Cyril;
Peoc’h, Michel

Publication type:

Article

Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1285, doi. 10.1007/s00262-018-2188-y

By:

Segatori, Valeria I.;
Cuello, Héctor A.;
Gulino, Cynthia A.;
Albertó, Marina;
Venier, Cecilia;
Guthmann, Marcelo D.;
Demarco, Ignacio A.;
Alonso, Daniel F.;
Gabri, Mariano R.

Publication type:

Article

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1271, doi. 10.1007/s00262-018-2186-0

By:

Leone, Robert D.;
Sun, Im-Meng;
Oh, Min-Hee;
Sun, Im-Hong;
Wen, Jiayu;
Englert, Judson;
Powell, Jonathan D.

Publication type:

Article

Longitudinal studies of the <sup>18</sup>F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1261, doi. 10.1007/s00262-018-2183-3

By:

Sachpekidis, Christos;
Anwar, Hoda;
Winkler, Julia K.;
Kopp-Schneider, Annette;
Larribere, Lionel;
Haberkorn, Uwe;
Hassel, Jessica C.;
Dimitrakopoulou-Strauss, Antonia

Publication type:

Article

Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1251, doi. 10.1007/s00262-018-2181-5

By:

Mølgaard, Kasper;
Harwood, Seandean L.;
Compte, Marta;
Merino, Nekane;
Bonet, Jaume;
Alvarez-Cienfuegos, Ana;
Mikkelsen, Kasper;
Nuñez-Prado, Natalia;
Alvarez-Mendez, Ana;
Sanz, Laura;
Blanco, Francisco J.;
Alvarez-Vallina, Luis

Publication type:

Article

Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1231, doi. 10.1007/s00262-018-2180-6

By:

Kimura, Hideki;
Matsui, Yukiko;
Ishikawa, Aki;
Nakajima, Takahiro;
Iizasa, Toshihiko

Publication type:

Article

Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1239, doi. 10.1007/s00262-018-2179-z

By:

Yin, Jun;
Albers, Alex J.;
Smith, Thomas S.;
Riddell, Geoffrey T.;
Richards, John O.

Publication type:

Article

Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1197, doi. 10.1007/s00262-018-2178-0

By:

Gauci, Marie-Léa;
Boudou, Philippe;
Baroudjian, Barouyr;
Vidal-Trecan, Tiphaine;
Da Meda, Laetitia;
Madelaine-Chambrin, Isabelle;
Basset-Seguin, Nicole;
Bagot, Martine;
Pages, Cécile;
Mourah, Samia;
Resche-Rigon, Matthieu;
Pinel, Sylvine;
Sassier, Marion;
Rouby, Franck;
Eftekhari, Pirayeh;
Lebbé, Céleste;
Gautier, Jean-François

Publication type:

Article

Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1209, doi. 10.1007/s00262-018-2176-2

By:

Ollier, Jocelyn;
Kervarrec, Thibault;
Samimi, Mahtab;
Benlalam, Houssem;
Aumont, Pascal;
Vivien, Régine;
Touzé, Antoine;
Labarrière, Nathalie;
Vié, Henri;
Clémenceau, Béatrice

Publication type:

Article

Targeting myeloid-derived suppressor cells for cancer immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1181, doi. 10.1007/s00262-018-2175-3

By:

Liu, Yijun;
Wei, Guowei;
Cheng, Wesley A.;
Dong, Zhenyuan;
Sun, Han;
Lee, Vincent Y.;
Cha, Soung-Chul;
Smith, D. Lynne;
Kwak, Larry W.;
Qin, Hong

Publication type:

Article

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 8, p. 1221, doi. 10.1007/s00262-018-2174-4

By:

Ben-Avi, Ronny;
Farhi, Ronit;
Ben-Nun, Alon;
Gorodner, Marina;
Greenberg, Eyal;
Markel, Gal;
Schachter, Jacob;
Itzhaki, Orit;
Besser, Michal J.

Publication type:

Article

Response to “Immune-mediated cholangitis: is it always nivolumab’s fault?”.

Published in:

2018

By:

Kashima, Jumpei;
Okuma, Yusuke

Publication type:

Letter to the Editor

Immune-mediated cholangitis: is it always nivolumab’s fault?

Published in:

2018

By:

Gelsomino, Francesco;
Vitale, Giovanni;
Ardizzoni, Andrea

Publication type:

Letter to the Editor